Patent ID: 9081013
Filing Date: 2015-07-14
Classification: G01N

Abstract:
1. A method of indicating the potential presence of early stage gastric cancer comprising: detecting COTL1 (coactosin-like 1) protein, and/or a variant thereof as a marker for detecting gastric cancer by incubating an anti-COTL1 antibody with a body fluid derived from a test subject under conditions in which the anti-COTL1 antibody binds COTL1 protein, and/or a variant thereof, measuring in vivo the amount of COTL1 protein, and/or a variant thereof present in the body fluid derived from the test subject, by incubating an anti-COTL1 antibody with the body fluid under conditions in which the anti-COTL1 antibody binds COTL1 protein, correlating an increase amount of COTL1 protein, and/or a variant thereof as compared with a normal amount of COTL1 protein, and/or a variant thereof present in body fluid with the presence of gastric cancer, and determining whether or not the test subject has gastric cancer on the basis of the amount, wherein the COTL1 protein is a polypeptide shown in SEQ ID NO: 1, wherein the variant is an amino acid sequence derived from the polypeptide shown in SEQ ID NO: 1 by the deletion, substitution, addition, or insertion of one or more amino acids, and that exhibits a percent identity to the polypeptide shown in SEQ ID NO: 1 of approximately 95% or higher, wherein if the amount of the marker for detecting gastric cancer in the test subject is statistically significantly larger than that of a normal individual, the test subject is determined to have gastric cancer, wherein the test subject is suspected of having gastric cancer, and wherein early stage gastric cancer is classified into stages 0 and/or I, and late stage gastric cancer is classified into stages II, III and/or IV.